Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

117 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
EMA and NICE Appraisal Processes for Cancer Drugs: Current Status and Uncertainties.
Dickson R, Boland A, Duarte R, Kotas E, Woolacott N, Hodgson R, Riemsma R, Grimm S, Ramaekers B, Joore M, Büyükkaramikli N, Kaltenthaler E, Stevenson M, Pandor A, Edwards S, Hoyle M, Shepherd J, Armoiry X, Brazzelli M. Dickson R, et al. Among authors: hoyle m. Appl Health Econ Health Policy. 2018 Aug;16(4):429-432. doi: 10.1007/s40258-018-0393-7. Appl Health Econ Health Policy. 2018. PMID: 29808296 Free PMC article. No abstract available.
The clinical effectiveness and cost-effectiveness of cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal No.150 and part review of technology appraisal No. 118): a systematic review and economic model.
Hoyle M, Crathorne L, Peters J, Jones-Hughes T, Cooper C, Napier M, Tappenden P, Hyde C. Hoyle M, et al. Health Technol Assess. 2013 Apr;17(14):1-237. doi: 10.3310/hta17140. Health Technol Assess. 2013. PMID: 23547747 Free PMC article. Review.
The clinical effectiveness and cost-effectiveness of cetuximab (review of technology appraisal no. 176) and panitumumab (partial review of technology appraisal no. 240) for previously untreated metastatic colorectal cancer: a systematic review and economic evaluation.
Huxley N, Crathorne L, Varley-Campbell J, Tikhonova I, Snowsill T, Briscoe S, Peters J, Bond M, Napier M, Hoyle M. Huxley N, et al. Among authors: hoyle m. Health Technol Assess. 2017 Jun;21(38):1-294. doi: 10.3310/hta21380. Health Technol Assess. 2017. PMID: 28682222 Free PMC article. Review.
Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia: systematic reviews and economic analyses.
Pavey T, Hoyle M, Ciani O, Crathorne L, Jones-Hughes T, Cooper C, Osipenko L, Venkatachalam M, Rudin C, Ukoumunne O, Garside R, Anderson R. Pavey T, et al. Among authors: hoyle m. Health Technol Assess. 2012;16(42):iii-iv, 1-277. doi: 10.3310/hta16420. Health Technol Assess. 2012. PMID: 23134589 Free article. Review.
Olaratumab in Combination with Doxorubicin for the Treatment of Advanced Soft Tissue Sarcoma: An Evidence Review Group Perspective of a National Institute for Health and Care Excellence Single Technology Appraisal.
Tikhonova IA, Jones-Hughes T, Dunham J, Warren FC, Robinson S, Stephens P, Hoyle M. Tikhonova IA, et al. Among authors: hoyle m. Pharmacoeconomics. 2018 Jan;36(1):39-49. doi: 10.1007/s40273-017-0568-3. Pharmacoeconomics. 2018. PMID: 28914440 Review.
The effectiveness and cost-effectiveness of erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating cancer treatment-induced anaemia (including review of technology appraisal no. 142): a systematic review and economic model.
Crathorne L, Huxley N, Haasova M, Snowsill T, Jones-Hughes T, Hoyle M, Briscoe S, Coelho H, Long L, Medina-Lara A, Mujica-Mota R, Napier M, Hyde C. Crathorne L, et al. Among authors: hoyle m. Health Technol Assess. 2016 Feb;20(13):1-588, v-vi. doi: 10.3310/hta20130. Health Technol Assess. 2016. PMID: 26907163 Free PMC article. Review.
The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model.
Bond M, Rogers G, Peters J, Anderson R, Hoyle M, Miners A, Moxham T, Davis S, Thokala P, Wailoo A, Jeffreys M, Hyde C. Bond M, et al. Among authors: hoyle m. Health Technol Assess. 2012;16(21):1-470. doi: 10.3310/hta16210. Health Technol Assess. 2012. PMID: 22541366 Free PMC article. Review.
117 results